210 related articles for article (PubMed ID: 33454199)
1. The additive value of mpMRI on prostate cancer detection: Comparison between patients with and without a suspicious digital rectal examination (DRE).
Omri N; Alex S; Jacob B; Ofer N
Urol Oncol; 2021 Oct; 39(10):728.e7-728.e11. PubMed ID: 33454199
[TBL] [Abstract][Full Text] [Related]
2. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
[TBL] [Abstract][Full Text] [Related]
3. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
4. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
Stabile A; Dell'Oglio P; Gandaglia G; Fossati N; Brembilla G; Cristel G; Dehò F; Scattoni V; Maga T; Losa A; Gaboardi F; Cardone G; Esposito A; De Cobelli F; Del Maschio A; Montorsi F; Briganti A
Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
[TBL] [Abstract][Full Text] [Related]
5. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
6. Is multiparametric MRI always needed in biopsy-naïve patients with abnormal digital rectal examination? A single-institutional experience combining clinical and micro-ultrasonography-based factors to optimize prostate cancer detection.
Avolio PP; Lazzeri M; Maffei D; Fasulo V; Frego N; Saitta C; de Carne F; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
World J Urol; 2024 Jan; 42(1):9. PubMed ID: 38183489
[TBL] [Abstract][Full Text] [Related]
7. MRI ultrasound fusion biopsy in prostate cancer detection: Are randomized clinical trials reproducible in everyday clinical practice?
Cattarino S; Forte V; Salciccia S; Drudi FM; Cantisani V; Sciarra A; Fasulo A; Ciccariello M
Urologia; 2019 Feb; 86(1):9-16. PubMed ID: 30890102
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
9. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer.
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2017 Feb; 15(1):e33-e36. PubMed ID: 27530436
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of usefulness of prostate specific antigen and digital rectal examination in the diagnosis of prostate cancer in an unscreened population:experience in a Nigerian teaching hospital.
Ojewola RW; Tijani KH; Jeje EA; Ogunjimi MA; Anunobi CC; Adesanya AO
West Afr J Med; 2013; 32(1):8-13. PubMed ID: 23613288
[TBL] [Abstract][Full Text] [Related]
11. Do all patients with suspicious prostate cancer need Multiparametric Magnetic Resonance Imaging before prostate biopsy?
Teixeira Anacleto S; Neves Alberto J; Carvalho Dias E; Sousa Passos P; Cerqueira Alves M
Arch Ital Urol Androl; 2022 Mar; 94(1):32-36. PubMed ID: 35352522
[TBL] [Abstract][Full Text] [Related]
12. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
13. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer.
Lughezzani G; Saita A; Lazzeri M; Paciotti M; Maffei D; Lista G; Hurle R; Buffi NM; Guazzoni G; Casale P
Eur Urol Oncol; 2019 May; 2(3):329-332. PubMed ID: 31200848
[TBL] [Abstract][Full Text] [Related]
15. Cancer detection rate of prebiopsy MRI with subsequent systematic and targeted biopsy are superior to non-targeting systematic biopsy without MRI in biopsy naïve patients: a retrospective cohort study.
Washino S; Kobayashi S; Okochi T; Kameda T; Konoshi T; Miyagawa T; Takayama T; Morita T
BMC Urol; 2018 May; 18(1):51. PubMed ID: 29843694
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric magnetic resonance imaging predicts the presence of prostate cancer in patients with negative prostate biopsy.
Lista F; Castillo E; Gimbernat H; Rodríguez-Barbero JM; Panizo J; Angulo JC
Actas Urol Esp; 2015 Mar; 39(2):85-91. PubMed ID: 25267460
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
[TBL] [Abstract][Full Text] [Related]
18. Can 3-Tesla pelvic phased-array multiparametric MRI avoid unnecessary repeat prostate biopsy in patients with PSA < 10 ng/mL?
Pepe P; Garufi A; Priolo G; Pennisi M
Clin Genitourin Cancer; 2015 Feb; 13(1):e27-30. PubMed ID: 25081324
[TBL] [Abstract][Full Text] [Related]
19. mpMRI-targeted biopsy of the prostate in men ≥ 75 years. 7-year report from a high-volume referral center.
Chaloupka M; Pyrgidis N; Ebner B; Pfitzinger PL; Volz Y; Berg E; Enzinger B; Atzler M; Ivanova T; Pfitzinger PL; Stief CG; Apfelbeck M; Clevert DA
Clin Hemorheol Microcirc; 2024; 86(1-2):63-70. PubMed ID: 37718788
[TBL] [Abstract][Full Text] [Related]
20. How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.
Borque-Fernando Á; Esteban LM; Celma A; Roche S; Planas J; Regis L; de Torres I; Semidey ME; Trilla E; Morote J
World J Urol; 2020 Jun; 38(6):1481-1491. PubMed ID: 31506748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
